Skip to main content
Top
Published in: Journal of Nephrology 1/2016

01-02-2016 | Original Article

Efficiency of delivery observed treatment in hemodialysis patients: the example of the native vitamin D therapy

Authors: Pierre Delanaye, Etienne Cavalier, Coraline Fafin, Bernard E. Dubois, Jean-Marie Krzesinski, Olivier Moranne

Published in: Journal of Nephrology | Issue 1/2016

Login to get access

Abstract

Introduction

Adherence to therapy is a relevant challenge in chronic hemodialysis patients. The directly observed therapy (DOT) could be an effective method to increase adherence for specific therapies. We aimed to study the performance of DOT versus home medication. We follow the impact of providing native vitamin D directly by the nurse after a dialysis session on the 25-hydroxyvitamin [25(OH)D] concentrations.

Methods

In this observational study, we included 38 dialysis patients treated by stable dosage of cholecalciferol. DOT was implemented in December 2010. We considered the concentrations of 25-OH vitamin D three times before (T1 = June 2010, T2 = July 2010 and T3 = September 2010) and three times after the modification of prescription (T4 = February 2011, T5 = March 2011 and T6 = April 2011).

Results

Median age was 72 [62; 79] years and 48 % were diabetics. Mean body mass index was 26 ± 5 kg/m2 and median dialysis vintage was 20 [8; 46] months. The patients were compared to themselves. Before DOT, median concentrations of 25(OH)D were 27 (14–36), 23 (17–31), 31 (22–38) ng/mL at T1, T2 and T3, respectively. When DOT was effective, the concentrations significantly increased to 34 (28–44), 35 (29–41), 39 (32–47) ng/mL at T4, T5 and T6, respectively. Before DOT, 19 patients (50 %) reached the target of 30 ng/mL. After DOT, 29 patients (76 %) reached the target concentration of 30 ng/mL.

Conclusions

In hemodialysis patients, DOT is both simple and effective to increase the therapeutic impact to native vitamin D.
Literature
1.
go back to reference Burnier M, Pruijm M, Wuerzner G, Santschi V (2015) Drug adherence in chronic kidney diseases and dialysis. Nephrol Dial Transplant 30(1):39–44PubMedCrossRef Burnier M, Pruijm M, Wuerzner G, Santschi V (2015) Drug adherence in chronic kidney diseases and dialysis. Nephrol Dial Transplant 30(1):39–44PubMedCrossRef
2.
go back to reference Neri L, Martini A, Andreucci VE, Gallieni M, Rey LA, Brancaccio D (2011) Regimen complexity and prescription adherence in dialysis patients. Am J Nephrol 34(1):71–76PubMedCrossRef Neri L, Martini A, Andreucci VE, Gallieni M, Rey LA, Brancaccio D (2011) Regimen complexity and prescription adherence in dialysis patients. Am J Nephrol 34(1):71–76PubMedCrossRef
3.
go back to reference Schmid H, Hartmann B, Schiffl H (2009) Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: a critical review of the literature. Eur J Med Res 14(5):185–190PubMedPubMedCentralCrossRef Schmid H, Hartmann B, Schiffl H (2009) Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: a critical review of the literature. Eur J Med Res 14(5):185–190PubMedPubMedCentralCrossRef
4.
go back to reference Karamanidou C, Clatworthy J, Weinman J, Horne R (2008) A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol 9:2PubMedPubMedCentralCrossRef Karamanidou C, Clatworthy J, Weinman J, Horne R (2008) A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol 9:2PubMedPubMedCentralCrossRef
5.
go back to reference Volmink J, Garner P (2007) Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev (4):CD003343 Volmink J, Garner P (2007) Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev (4):CD003343
6.
go back to reference (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl (113):S1–S130 (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl (113):S1–S130
7.
go back to reference Cavalier E, Delanaye P, Moranne O (2013) Variability of new bone mineral metabolism markers in patients treated with maintenance hemodialysis: implications for clinical decision making. Am J Kidney Dis 61(5):847–848PubMedCrossRef Cavalier E, Delanaye P, Moranne O (2013) Variability of new bone mineral metabolism markers in patients treated with maintenance hemodialysis: implications for clinical decision making. Am J Kidney Dis 61(5):847–848PubMedCrossRef
8.
go back to reference Delanaye P, Weekers L, Warling X et al (2013) Cholecalciferol in haemodialysis patients: a randomized, double-blind, proof-of-concept and safety study. Nephrol Dial Transplant 28(7):1779–1786PubMedCrossRef Delanaye P, Weekers L, Warling X et al (2013) Cholecalciferol in haemodialysis patients: a randomized, double-blind, proof-of-concept and safety study. Nephrol Dial Transplant 28(7):1779–1786PubMedCrossRef
9.
go back to reference Cavalier E, Delanaye P, Chapelle JP, Souberbielle JC (2009) Vitamin D: current status and perspectives. Clin Chem Lab Med 47(2):120–127PubMedCrossRef Cavalier E, Delanaye P, Chapelle JP, Souberbielle JC (2009) Vitamin D: current status and perspectives. Clin Chem Lab Med 47(2):120–127PubMedCrossRef
10.
go back to reference Wolf M, Shah A, Gutierrez O et al (2007) Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72(8):1004–1013PubMedCrossRef Wolf M, Shah A, Gutierrez O et al (2007) Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72(8):1004–1013PubMedCrossRef
11.
go back to reference Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32(5 Suppl 3):S112–S119PubMedCrossRef Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32(5 Suppl 3):S112–S119PubMedCrossRef
12.
go back to reference Kangovi S, Mukherjee J, Bohmer R, Fitzmaurice G (2009) A classification and meta-analysis of community-based directly observed therapy programs for tuberculosis treatment in developing countries. J Community Health 34(6):506–513PubMedCrossRef Kangovi S, Mukherjee J, Bohmer R, Fitzmaurice G (2009) A classification and meta-analysis of community-based directly observed therapy programs for tuberculosis treatment in developing countries. J Community Health 34(6):506–513PubMedCrossRef
13.
go back to reference Hill AR, Manikal VM, Riska PF (2002) Effectiveness of directly observed therapy (DOT) for tuberculosis: a review of multinational experience reported in 1990–2000. Medicine (Baltimore) 81(3):179–193CrossRef Hill AR, Manikal VM, Riska PF (2002) Effectiveness of directly observed therapy (DOT) for tuberculosis: a review of multinational experience reported in 1990–2000. Medicine (Baltimore) 81(3):179–193CrossRef
14.
go back to reference Hart JE, Jeon CY, Ivers LC et al (2010) Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review. J Acquir Immune Defic Syndr 54(2):167–179PubMedPubMedCentral Hart JE, Jeon CY, Ivers LC et al (2010) Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review. J Acquir Immune Defic Syndr 54(2):167–179PubMedPubMedCentral
15.
go back to reference Bhan I, Camargo CA Jr, Wenger J et al (2011) Circulating levels of 25-hydroxyvitamin D and human cathelicidin in healthy adults. J Allergy Clin Immunol 127(5):1302–1304PubMedPubMedCentralCrossRef Bhan I, Camargo CA Jr, Wenger J et al (2011) Circulating levels of 25-hydroxyvitamin D and human cathelicidin in healthy adults. J Allergy Clin Immunol 127(5):1302–1304PubMedPubMedCentralCrossRef
16.
go back to reference Jean G, Lataillade D, Genet L et al (2011) Impact of hypovitaminosis D and alfacalcidol therapy on survival of hemodialysis patients: results from the French ARNOS study. Nephron Clin Pract 118(2):c204–c210PubMedCrossRef Jean G, Lataillade D, Genet L et al (2011) Impact of hypovitaminosis D and alfacalcidol therapy on survival of hemodialysis patients: results from the French ARNOS study. Nephron Clin Pract 118(2):c204–c210PubMedCrossRef
17.
go back to reference Armas LA, Andukuri R, Barger-Lux J, Heaney RP, Lund R (2012) 25-Hydroxyvitamin D response to cholecalciferol supplementation in hemodialysis. Clin J Am Soc Nephrol 7(9):1428–1434PubMedPubMedCentralCrossRef Armas LA, Andukuri R, Barger-Lux J, Heaney RP, Lund R (2012) 25-Hydroxyvitamin D response to cholecalciferol supplementation in hemodialysis. Clin J Am Soc Nephrol 7(9):1428–1434PubMedPubMedCentralCrossRef
18.
go back to reference Massart A, Debelle FD, Racape J et al (2014) Biochemical parameters after cholecalciferol repletion in hemodialysis: results from the VitaDial randomized trial. Am J Kidney Dis 64(5):696–705PubMedCrossRef Massart A, Debelle FD, Racape J et al (2014) Biochemical parameters after cholecalciferol repletion in hemodialysis: results from the VitaDial randomized trial. Am J Kidney Dis 64(5):696–705PubMedCrossRef
19.
go back to reference Wasse H, Huang R, Long Q, Singapuri S, Raggi P, Tangpricha V (2012) Efficacy and safety of a short course of very-high-dose cholecalciferol in hemodialysis. Am J Clin Nutr 95(2):522–528PubMedPubMedCentralCrossRef Wasse H, Huang R, Long Q, Singapuri S, Raggi P, Tangpricha V (2012) Efficacy and safety of a short course of very-high-dose cholecalciferol in hemodialysis. Am J Clin Nutr 95(2):522–528PubMedPubMedCentralCrossRef
20.
go back to reference Jean G, Souberbielle JC, Chazot C (2009) Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation. Nephrol Dial Transplant 24(12):3799–3805PubMedCrossRef Jean G, Souberbielle JC, Chazot C (2009) Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation. Nephrol Dial Transplant 24(12):3799–3805PubMedCrossRef
Metadata
Title
Efficiency of delivery observed treatment in hemodialysis patients: the example of the native vitamin D therapy
Authors
Pierre Delanaye
Etienne Cavalier
Coraline Fafin
Bernard E. Dubois
Jean-Marie Krzesinski
Olivier Moranne
Publication date
01-02-2016
Publisher
Springer International Publishing
Published in
Journal of Nephrology / Issue 1/2016
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-015-0196-y

Other articles of this Issue 1/2016

Journal of Nephrology 1/2016 Go to the issue

Acknowledgement to Referees

Thanks to Reviewers 2015

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.